Abstract #4600: Chk1 inhibitors override the DNA damage checkpoint and enhance anti-tumor activity of irinotecan in p53-deficient tumor xenografts in mice
Joe Davide(United States Military Academy), Weikang Tao(Shanghai Medical Information Center), Vadim Dudkin(United States Military Academy), Ron Diehl(United States Military Academy), Mark E. Fraley(United States Military Academy), Rob Garbaccio(United States Military Academy), Vicki J. South(United States Military Academy), Laura Sepp‐Lorenzino(Intellia Therapeutics (United States)), Rob Lobell(United States Military Academy)
Cancer Research
May 1, 2009
Cited by 0
Related Papers
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
|New England Journal of Medicine|2021|1.7k
Total Synthesis of Spirotryprostatin A, Leading to the Discovery of Some Biologically Promising Analogues
|Journal of the American Chemical Society|1999|463
Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90
|Proceedings of the National Academy of Sciences|1996|409
A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines.
|PubMed|1995|385
Micro RNA 145 Targets the Insulin Receptor Substrate-1 and Inhibits the Growth of Colon Cancer Cells
|Journal of Biological Chemistry|2007|356